A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer ...

Thromboembolic events in immunomodulatory drug (IMiD)–sparing regimens for patients with newly diagnosed multiple myeloma (NDMM). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

England’s NHS has launched a groundbreaking “Trojan Horse” therapy for the treatment of myeloma, offering hope for thousands ...

Karolinska University Hospital has, for the first time in Sweden, begun preparations to treat a patient with multiple myeloma ...

Multiple myeloma — cancer of the white blood cells known as plasma cells — can cause a vast spectrum of symptoms as it progresses. But multiple myeloma often has no outward signs in its early ...

Trends and disparities patterns in CAR-T therapy utilization, inpatient mortality, and adverse events in the United States (2017–2021). This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

In An Exercise in Uncertainty, Jon Gluck traces decades of waiting, watching, enduring experimental treatment, and miraculously beating the odds.

Plasma cell leukemia (PCL) is a rare disease that may present de novoor secondary to plasma cell myeloma. Advanced disease and extramedullary involvement are common clinical features at presentation.